Drug reaction with eosinophilia and systemic symptoms syndrome probably induced by a lamotrigine-ginseng drug interaction

Pharmacotherapy

Volumn 35, Issue 3, 2015, Pages e9-e12

  Myers, Amy P ^a   Watson, Troy A ^b   Strock, Steven B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

DRESS; drug interaction; ginseng; lamotrigine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CIPROFLOXACIN; CREATINE KINASE; DEER ANTLER VELVET; FERRITIN; GINSENG EXTRACT; HERBACEOUS AGENT; HYDROCORTISONE; IMMUNOGLOBULIN G; LAMOTRIGINE; METHYLPREDNISOLONE; NAPROXEN; PARACETAMOL; PENICILLIN DERIVATIVE; SILDENAFIL; UNCLASSIFIED DRUG; UROBILINOGEN; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADULT; ARTICLE; CASE REPORT; CHEST TIGHTNESS; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; ECHOGRAPHY; ELECTROENCEPHALOGRAPHY; EOSINOPHIL COUNT; EOSINOPHILIA; EPSTEIN BARR VIRUS; ERYTHROCYTE SEDIMENTATION RATE; FERRITIN BLOOD LEVEL; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIVER FUNCTION TEST; MALE; MEDICAL HISTORY; MONOSPOT TEST; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATITIS; PROTEIN BLOOD LEVEL; RASH; SCREENING TEST; SEIZURE; TONIC CLONIC SEIZURE; URINALYSIS; URINE COLOR; VOMITING; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG HYPERSENSITIVITY SYNDROME; HERB DRUG INTERACTION; METABOLISM; PANAX;

ADULT; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY SYNDROME; EOSINOPHILIA; HERB-DRUG INTERACTIONS; HUMANS; MALE; PANAX; TRIAZINES;

EID: 84925611823     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1550     Document Type: Article

References (21)

1. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013; 169: 1071-80.
2. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156: 609-11.
3. Lee T, Lee YS, Yoon SY, et al. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions [abstract 1]. J Am Acad Dermatol 2013; 69: 407-15. Epub 2013 Apr 28.
4. Piñana E, Lei SH, Merino R, et al. DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpevirus 6 in an 11-year-old Caucasian boy [abstract 1]. J Clin Pharm Ther 2010; 35: 365-70.
5. Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149: 1018-22.
6. Criado PR, Avancini J, Santi CG, Medrado AT, Rodrigues CE, de Carvalho JF,. Drug reaction with eosinophilia and systemic symptoms (DRESS): a complex interaction of drugs, viruses and the immune system. Isr Med Assoc J 2012; 14: 577-82.
7. Bohan KH, Mansuri TF, Wilson NM,. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007; 27: 1425-39.
8. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124: 588-97. Epub 2011 May 17.
9. Rahman M, Haider N,. Anticonvulsant hypersensitivity syndrome from addition of lamotrigine to divalproex [letter to the editor]. Am J Psychiatry 2005; 162: 1021.
10. Greiner C, Wittmann M, Haen E,. Lamotrigine serum concentrations under valproate comedication: "contraindication" or "safe combination"? A case report. Pharmacopsychiatry 2007; 40: 287-9.
11. Gidal BE, Sheth R, Parnell J, Maloney K, Sale M,. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy [abstract 1]. Epilepsy Res 2003; 57: 85-93.
12. Information P,. LAMICTAL chewable dispersible oral tablets, oral tablets, orally disintegrating tablets, lamotrigine chewable dispersible oral tablets, oral tablets, orally disintegrating tablets. Research Triangle Park, NC: GlaxoSmithKline; 2009.
13. Morris R, Black A, Lam E, et al. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage. Ther Drug Monit 2000; 22: 656-60.
14. Burstein AH,. Lamotrigine. Pharmacotherapy 1995; 15: 129-43.
15. Anderson GD,. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32: 554-63.
16. Kocak S, Girisgin SA, Gul M, et al. Stevens-Johnson syndrome due to concomitant use of lamotrigine and valproic acid. Am J Clin Dermatol 2007; 8: 107-11.
17. Page RL II, O'Neil MG, Yarbrough DR III, et al. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998; 18: 392-8.
18. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO,. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006; 34: 1055-62. Epub 2006 Mar 24.
19. Zheng YF, Bae SH, Choi EJ, et al. Evaluation of the in vitro/in vivo drug interaction potential of BST204, a purified dry extract of ginseng, and its four bioactive ginsenosides through cytochrome P450 inhibition/induction and UDP-glucuronosyltransferase inhibition. Food Chem Toxicol 2014; 68: 117-27. Epub 2014 Mar 12.
20. Horn JR, Hansten PD, Chan LN,. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674-80. Epub 2007 Mar 27.
21. DeVane CL,. Evidence for drug exposure causally associated with adverse events. Pharmacotherapy 2013; 33: 115-7.